Pharmaceuticals
Novavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...
2022-03-10 22:00
5410
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
SHANGHAI, March 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI), evaluating cefepime-taniborbactam, an in...
2022-03-10 19:05
4782
Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
SUZHOU, China, March 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta has ...
2022-03-10 08:30
4434
Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis
- Cystinosis is a rare genetic disease affecting 1 in 100,000-200,000 live births and poses a lifelong risk to those affected. Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain. - There are currently no curative treatme...
2022-03-10 00:57
3250
Kusum Healthcare recognized as one of Best Places to Work in Philippines for 2022
MANILA, Philippines, March 9, 2022 /PRNewswire/ -- Kusum Healthcare, a leading tech-driven pharmaceutical group, has been recently awarded the Best Place to Work certification inPhilippines for 2022. During the company assessment, 97% of employees recommended the organization illustrating the com...
2022-03-09 20:22
2565
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. ...
2022-03-09 19:08
4200
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
* New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company's AI-powered platform - * SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, de...
2022-03-09 10:21
4262
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022
SUZHOU, China, March 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (KN026-203) of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented by E- poster at the 113th American Associa...
2022-03-09 09:14
2985
SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory inCopenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and...
2022-03-08 15:31
2126
Nippon Express USA Acquires GDP Certification for CFS in Los Angeles and New York
TOKYO, March 8, 2022 /PRNewswire/ -- Nippon Express USA, Inc. (hereinafter "NX USA"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at temperature-controlled facilities in it...
2022-03-08 14:00
3713
Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management
Alongside brand refresh, leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey. PHILADELPHIA, March 8, 2022 /PRNewswire/ -- Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a g...
2022-03-08 08:00
2424
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs
TAIPEI, March 7, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract dev...
2022-03-07 09:00
2896
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technolo...
2022-03-07 09:00
3301
Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
GENEVA, March 4, 2022 /PRNewswire/ -- To mark International HPV Awareness Day
March 4th 2022, the International Papillomavirus Society (IPVS) has warmly
welcomed two major advances in the elimination of cervical and anal cancers.
2022-03-04 08:01
4606
Sequential Skin debuts Sequential Bio - the world's first in-vivo microbiome testing solution for skin, hair, and personal product industries.
LONDON, NEW YORK and SINGAPORE, March 3, 2022 /PRNewswire/ -- Sequential Skin
Ltd, a leading microbiome company today announced the debut ofSequential Bio
2022-03-03 07:55
3554
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
SAN DIEGO and SUZHOU, China, Mar. 2, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispe...
2022-03-02 19:00
4741
Cambrex Expands Biopharmaceutical Services Business
EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...
2022-03-01 22:00
4208
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketin...
2022-03-01 17:30
4189
Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant
* The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 * SPL7013 showed potent antiviral activity and was virucidal against the Omicron varia...
2022-03-01 16:44
3064
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-03-01 08:48
4267
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
19798
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
17556
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
7917